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What expert breeders have done for 
dogs and apple trees, the biotech 
company Maxygen Inc. is doing for 
commercially important molecules 
- -  breeding them to come up with 
better alternatives. The technique is 
straightforward, says Maxygen's 
Dutch-born chief scientist and co- 
founder Pim Stemmer, upon whose 
work the company's technology is
based. "Even a child can breed dogs 
or vegetables - - the trick is to just 
look at the appearance and select for 
it," says Stemmer. 
It is a trick that has led to two 
recent jackpots for Maxygen 
(Redwood City, California). In March, 
DSM Anti-Infectives of Delft, the 
Netherlands, paid an undisclosed 
amount o Maxygen to use its 
technique to rapidly evolve enzymes 
to manufacture antibiotics. And in 
January, Maxygen signed a deal for a 
potential $85 million to apply its 
evolution-while-you-wait regimen to 
food plants like corn on behalf of 
Pioneer Hi-Bred International Inc. of 
Des Moines, Iowa (later swallowed by 
DuPont), the world's largest producer 
of seed corn. 
A charmed approach 
Maxygen's technique of gene 
shuffling, as molecular breeding is 
also known, is "charmed," says Laura 
Landweber, a professor of molecular 
biology at Princeton University in 
Princeton, New Jersey, because it
"starts from a mixture of nature's best 
attempts" and then seeks to improve 
them still further. Landweber herself 
investigates the way lower organisms 
like ciliates shuffle their own genes 
during reproduction. Maxygen's 
version of the technique, she says, 
"captures the very forces of evolution 
that give rise to life i tsel f - -  the 
combinatorial forces that first put 
together functional genes." 
The molecular breeding approach 
parts company with the premise of 
the first wave of 'evolutionary 
biotechnology' companies in the 
early 1990s. Then, academics- 
turned-biotechnologists attempted to 
evolve catalysts and other functional 
molecules out of RNA. The problem 
there, says Landweber, was that 
many of these approaches "ran up 
against he brick wall of trying to 
convince RNA to catalyze reactions 
other than [those for which RNA 
catalysts had originally evolved]". 
By breeding molecules like cattle, 
Maxygen is improving detergents 
and drugs. 
By taking on the ostensibly more 
difficult task of applying multiple 
rounds of mutation and selection on 
noncoding molecules like proteins, 
Maxygen has succeeded where many 
of its predecessors have not. 
Irrational drug design 
The technique of gene shuffling had 
its roots in Stemmer's early 
frustration with yet another hyped 
technique in drug discovery: 
structure-based design. While 
working at the biotech company 
Hybritech in San Diego in the late 
1980s and early 1990s, Stemmer was 
"disgusted" at the limitations of so- 
called "rational" design. It yielded 
"just snapshots", herecalls. 
Falling back on his Ph.D. work at 
the University of Wisconsin, which 
included some agriculture courses, 
Stemmer decided to strike out in a 
new direction. Why not build 
libraries of proteins in the test tube, 
then mix and match the genes that 
coded for these proteins in order to 
evolve optimal molecules? Such a 
technique could capitalize on the 
piles of sequences emerging from the 
Human Genome Project. 
The technique works like this. In 
the first round, Maxygen begins with 
the diversity already present in a 
family of related (homologous) 
genes. The company then rapidly 
'shuffles' all this diversity to create a 
larger pool of novel genes. Genes are 
fragmented into small pieces and 
reassembled based on their original 
DNA sequences. Then the genes are 
cloned into bacteria or cells and their 
protein products are screened for 
activity. A pool of the best sequences 
is then simultaneously shuffled and 
multiplied again using a process 
based on polymerase chain reaction, 
then screened again. In a 1994 Nature 
paper, Stemmer showed he had 
improved the r sistance of a 
bacterium to antibiotics by a factor of 
32,000 by shuffling its genes. 
Conventional techniques of 
mutagenesis had achieved just a 
16-fold improvement. 
Winning is the only thing 
Stemmer learned early that there 
would be two keys to making such a 
library approach successful. First, he 
would need excellent assays, 
empirical tests that could determine 
which individuals in a population of 
molecules were the 'winners' at 
some biochemical task. From the 
first, Stemmer took an utterly 
pragmatic approach. The better the 
assays could mimic the task the 
winners would later be expected to 
perform, the more suited these 
winners would be. If he could not 
think of a sure-fire assay, Stemmer 
chose a different problem. 
Second, Stemmer once again 
distanced himself rom his 
competitors in making libraries. 
Many competitors chose to generate 
huge libraries of millions or even 
billions of molecules, which were 
then laboriously sieved. But this 
approach was like starting "galaxies 
away" from the eventual successes, 
says Stemmer, and then working 
one's way back. Stemmer, by 
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contrast, started with families of 
related genes exhibiting some 
functionality, permutated them and 
generated further variations on these 
already productive themes 
(Figure 1). This has led to a double 
benefit: the libraries he generates are 
both smaller and more fertile than 
those resulting from more random 
approaches. 
Furthermore, because Maxygen 
chooses the early winners based on 
their performance in assays rather 
than due to particular structural or 
biological features, shuffling departs 
from what Stemmer calls 
"knowledge-based approaches" to 
biotechnology. "We don't have to 
know how many genes are on a piece 
of DNA, the sequence of genes or 
which gene regulates which. We can 
evolve DNA without any sequence 
information at all," he says, "just like 
a child breeding dogs." 
Kneeling before nature 
This empiricism "makes an 
academic scientist just cringe," says 
Ronald Breaker of Yale University in 
New Haven, a specialist at evolving 
DNA for many novel purposes. But 
for Stemmer, remaining empirical is 
a sign of humility. "Our approach 
shows respect for the complexity of 
biological interactions" in strong 
contrast to the hubris of, say, 
structure-based design. "The more 
complex the biology, the more 
appropriate a breeding approach is," 
Stemmer adds. 
The real power of shuffling has 
begun to emerge in even more 
complex proofs of concept. Maxygen 
has applied the 'family shuffling' 
technique on 26 variants of the gene 
for the detergent enzyme subtilisin. 
These genes were already highly 
'engineered', some were patented 
and the pool included the 'optimal' 
version of subtilisin already in use in 
laundry detergents. In a single cycle 
of shuffling and testing, the team 
obtained subtilisin 'offspring' that 
were improved over the parents in
three different properties (activity at 
high pH, thermal stability and 
solvent stability) simultaneously. 
Finally, a Maxygen group 
recently shuffled genes coding for 
the billion-US-dollar anticancer and 
antiviral drug interferon-c~. The 
group shuffled a pool of diverse 
human genes for interferon-0~ and, 
after applying 68 assays, were able to 
show a 135,000-fold improvement in 
the molecule's ability to protect 
mouse cells from infection by a virus. 
Growing pains? 
All of these successes, and the two 
recent deals, contribute to a frenetic 
atmosphere atthe company's 
headquarters ata eucalyptus- 
scented technology park on the 
shores of San Francisco Bay. "Before 
we'd even moved in" in March, 
observes Maxygen scientist Ling 
Yuan, "we'd already outgrown our 
space." The company, which is a 
now-independent spin-out from the 
Affymax Research Institute, which 
in turn belongs to multinational 
pharmaceutical giant Glaxo 
Wellcome, has grown from 25 
people in early 1998 to a whopping 
100 in 1999, with more growth 
presumably to come. 
The company will need all that 
energy and more to face the dual 
challenges of applying shuffling to 
drugs and plants. All of the 
company's prior work--such as its 
collaboration with Danish detergent 
enzyme king Novo Nordisk--  has 
shied away from actual drug 
discovery. Now the company plans to 
tackle "more enzymes affecting 
secondary metabolites," especially in 
the pharmaceuticals rea, where 
assay development is not so easy, 
says Jeremy Minshull, a Maxygen 
group leader in core technologies. It 
is the company's avowed goal to use 
shuffling to improve protein 
pharmaceuticals such as antibodies, 
growth factors and vaccines, though 
no corporate deals have yet been 
announced. 
Gene shuffling in plants, too, 
presents its own perils. On the one 
hand, agricultural companies are 
much more aware of the advantages of
breeding--"we got the $85 million 
deal without having published a
paper" observes Yuan. At the same 
time, once the targets reach beyond 
specific genes in corn or other food 
plants, Maxygen will need to shuffle 
entire pathways of genes in order to 
see an effect. And pathways, ays 
Richard Michelmore, professor of 
vegetable crops at the University of 
California at Davis, "are remarkably 
homeostatic. Tweak one thing and the 
organism compensates," sometimes n 
unexpected ways. Still, Michelmore 
agrees, "engineering whole pathways 
is where the future is." 
Perhaps the biggest hurdle facing 
Maxygen will be its ability to 
maintain its high success rate under 
conditions of rapid growth. Silicon 
Valley is littered with examples of 
high-tech companies that grew too 
fast, resulting in a loss of focus. The 
company's broader success will 
depend on how well the company 
can teach its techniques to its many 
new employees. There, too, 
Stemmer is optimistic. After all, if a 
child can learn to breed, how hard 
can it be for a Ph.D.? 
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